How effective is crizotinib when it enters the brain?

Crizotinib is a targeted drug for the treatment of non-small cell lung cancer. Crizotinib has poor blood-brain barrier permeability. Crizotinib is not ineffective in patients with brain metastases. The intracranial objective response rate of crizotinib in treating brain metastases is about 50%, but the time to control intracranial lesions is shorter than that of lesions in other parts of the body.

Crizotinib is a targeted drug therapy called a tyrosine kinase inhibitor (TKI) that kills cancer cells by targeting specific areas of the genes that cause cancer. Crizotinib treatment helps slow down or shrink the size of ALK positive (ALK+)non-small cell lung cancer (NSCLC) patients 10.9 months and ROS1+ Lung cancer tumor growth in NSCLCpatients18.3 months. In a small number of patients, their tumors go undetected after treatment (called a complete response), but that doesn't mean their cancer is cured. In a clinical study of 26 patients with ALK+anaplastic large cell lymphoma(ALCL), 88% responded to crizotinib treatment. Of the 23 patients who responded, 5 patients (22%) remained responsive 12 months after starting treatment. In anaplastic lymphoma kinase(ALK)positive inflammatory myofibroblastoma(ALK+ IMT), 12 out of 14 children (86%) and 7 out of 7 adults 5patients (71%) experienced objective response (complete response or partial response to treatment), which is the primary endpoint, and duration of response from6It ranges from 12 months to 12 months. Both Bangladesh and Laos pharmaceutical factories produce it. The retail price of Laos pharmaceutical factory is about 2 more than 2 per box, and the retail price of Bangladeshi pharmaceutical factory is about 2,000 to 3,000. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.